Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided pages of the document. The discussion primarily focuses on operational performance, R&D spend, product launches, market expansion, litigation, tax rates, and strategic initiatives. No statements or guidance related to raising capital via debt or equity were noted.

Any current/future capex/capital investment/strategic investment?

The company is commissioning a new facility as part of a joint venture (JV) related to Perfect Day, aimed at setting up a Contract Development and Manufacturing Organization (CDMO) facility. (Page 8, 9) The wellness business acquisition, including RiteBite Max Protein, is about INR 130 crores in annual revenue and focuses on healthy snacking and nutrition space. (Page 8) The company is investing in building end-to-end infrastructure and capabilities to be a long-term player in the US animal health space. (Page 13) A significant part of R&D spending—around 8% of revenue—is sustained for develop

Future growth expectations in sales/revenue/volumes?

India business aims to grow better than market with focus on innovative and growth booster brands driving sustained growth. Emerging markets expected strong double-digit revenue and faster profitability growth, leveraging global product portfolio and new markets (UK, Australia, Canada). US business to grow in FY26 over FY25 despite competition (Asacol), with major launches planned in FY27 and FY28 offering large opportunities. Mirabegron is expected to continue growing quarter on quarter and remains a major product in FY26. FY26 to see meaningful opportunities from Sitagliptin 505(b)(2

Future growth expectations in earnings/operating earnings/profits/EPS?

FY26 US business is expected to grow over FY25 despite competition (e.g., Asacol). FY27 and FY28 anticipated to be significantly larger due to assured Day 1 exclusive product launches. Mirabegron remains a growing product quarter-on-quarter, contributing to sustained growth. Overall, the company is on track to achieve aspirational growth and profitability for FY25. EBITDA margin guidance for FY25 remains at around 27%, with expectations for 100-150 bps improvement over the previous year. India branded formulations business targets better-than-market growth, supported by a growing chronic portf

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention exact figures or details about the current or expected orderbook/pending orders. There is a mention of tenders expected to last 2-3 years, indicating potential sizeable opportunities. Competition is limited to 1-3 players, suggesting a good chance of meaningful wins. On the US side, the company has a strong pipeline with upcoming product launches, including exclusive Day 1 launches expected in FY27 and FY28, signaling a growing portfolio and order potential. The company is also building capabilities for new product commercialization like gadolinium MR

IN US

Sale is live|00:00:00left today

Zydus Lifesciences LtdQ3 FY24Pharmaceuticals & Biotechnology

Zydus Lifesciences Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,116P/E: 19.9Market Cap: ₹1.0L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→India business aims to grow better than market with focus on innovative and growth booster brands driving sustained growth.
→Emerging markets expected strong double-digit revenue and faster profitability growth, leveraging global product portfolio and new markets (UK, Australia, Canada).
→US business to grow in FY26 over FY25 despite competition (Asacol), with major launches planned in FY27 and FY28 offering large opportunities.
→Mirabegron is expected to continue growing quarter on quarter and remains a major product in FY26.
→FY26 to see meaningful opportunities from Sitagliptin 505(b)(2), injectables, and internal pipeline products.
→R&D spend sustained around 8% of revenue to support portfolio expansion and innovation for long-term growth.
→Overall, the company is on track to achieve aspirational growth and profitability for FY25 and beyond with a strong product pipeline.

Margin guidance

Category 3

→FY26 US business is expected to grow over FY25 despite competition (e.g., Asacol).
→FY27 and FY28 anticipated to be significantly larger due to assured Day 1 exclusive product launches.
→Mirabegron remains a growing product quarter-on-quarter, contributing to sustained growth.
→Overall, the company is on track to achieve aspirational growth and profitability for FY25.
→EBITDA margin guidance for FY25 remains at around 27%, with expectations for 100-150 bps improvement over the previous year.
→India branded formulations business targets better-than-market growth, supported by a growing chronic portfolio (now >41% of domestic business).
→Emerging markets are expected to continue strong double-digit revenue and profitability growth despite challenges.
→R&D spend planned at ~8% of revenue, supporting innovation and future product launches.
→No new upward or downward revision to FY25 estimates; current guidance remains valid.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising through debt or equity in the provided pages of the document.
→The discussion primarily focuses on operational performance, R&D spend, product launches, market expansion, litigation, tax rates, and strategic initiatives.
→No statements or guidance related to raising capital via debt or equity were noted.

Order book

→The transcript does not explicitly mention exact figures or details about the current or expected orderbook/pending orders.
→There is a mention of tenders expected to last 2-3 years, indicating potential sizeable opportunities. Competition is limited to 1-3 players, suggesting a good chance of meaningful wins.
→On the US side, the company has a strong pipeline with upcoming product launches, including exclusive Day 1 launches expected in FY27 and FY28, signaling a growing portfolio and order potential.
→The company is also building capabilities for new product commercialization like gadolinium MRI injectables.
→Overall, Zydus Lifesciences is optimistic about future business growth driven by new launches, portfolio reorganization, and specialty/chronic portfolio expansion, which underpins expected demand and orders.

Capex plans

Yes

→The company is commissioning a new facility as part of a joint venture (JV) related to Perfect Day, aimed at setting up a Contract Development and Manufacturing Organization (CDMO) facility. (Page 8, 9)
→The wellness business acquisition, including RiteBite Max Protein, is about INR 130 crores in annual revenue and focuses on healthy snacking and nutrition space. (Page 8)
→The company is investing in building end-to-end infrastructure and capabilities to be a long-term player in the US animal health space. (Page 13)
→A significant part of R&D spending—around 8% of revenue—is sustained for developing complex generics, biologics, NCEs, and US clinical development, including a large Phase III trial. (Page 21)
→The company continues to focus on innovation and portfolio expansion with multiple new launches and pipeline developments planned in FY27 and FY28. (Page 19, 21)

How does Zydus Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Zydus Lifesciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Zydus Lifesciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio